⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21001647 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL22392350 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL21001649 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL1132190 | 0.97 | — | — | |
| SCHEMBL18266878 | 0.75 | — | — | |
| SCHEMBL2860713 | 0.75 | — | — | |
| SCHEMBL3367148 | 0.75 | — | — | |
| SCHEMBL10629749 | 0.75 | — | — | |
| SCHEMBL8420119 | 0.75 | — | — | |
| SCHEMBL13476029 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564547-B2 | Compositions, formulations, and methods for skin treatment | ODDITY LABS, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| WO-2023133240-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | REVELA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-3713922-A1 | SULPHUR SUBSTITUTED 3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | Bayer Aktiengesellschaft (DE) | 2020-09-30 | — | — | EP | disclosed |
| WO-2020025030-A1 | PREPARATION AND APPLICATION OF AROMATIC COMPOUND HAVING IMMUNOREGULATORY FUNCTION | 上海轶诺药业有限公司 | 2020-02-06 | — | — | WO | disclosed |
| WO-2020024997-A1 | PREPARATION AND APPLICATION OF CLASS OF N-CONTAINING HETEROCYCLIC COMPOUNDS HAVING IMMUNOREGULATORY FUNCTION | 上海轶诺药业有限公司 | 2020-02-06 | — | — | WO | disclosed |
| WO-2019101642-A1 | SULPHUR SUBSTITUTED 3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-05-31 | — | — | WO | disclosed |
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20080032969-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2008-02-07 | — | — | US | disclosed |
| US-7323472-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-7314934-B2 | 4-amino substituted-6-aryl/heteroaryl substituted-2-methylsulfanyl-pyrimidine-5-carbaldehyde intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314881-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| EP-1333833-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20050203109-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2005-09-15 | — | — | US | disclosed |
| US-20040209901-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | disclosed |
| EP-1333833-A2 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002059083-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |